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Placental Growth Factor: A review of literature and future applications 
 
Introduction: 
Placental growth factor is an angiogenic protein, highly expressed during pregnancy, which 
correlates well with placental function. In this review, we highlight the origin, structure and function 
of Placental Growth Factor and its receptors. We discuss how their pro-angiogenic/anti-angiogenic 
synergism is critical for successful placentation and how their imbalance may be utilised as a 
diagnostic marker of disease or a potential therapeutic target for adverse pregnancy outcomes. .  
 
Discovery, Structure & Function   
Placental growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of 
proteins. Crystallography resolution at 2.0 Å resolution shows PlGF to have a three-dimensional 
structure comprising of 149–amino-acids. Comparison with that of VEGF-A shows a remarkable 
similarity between the two proteins, with  53% sequence identity between amino acids from 
positions 39-132 of PlGF and amino acids from positions 38-131 of VEGF-A. (1, 2) PlGF was the 
second member of the vascular endothelial growth factor (VEGF) family identified, VEGF-A having 
been described in 1989. (3-5) PlGF, like all proteins of the VEGF family, is a secreted dimeric 
glycoprotein with a distinctive cystine knot. This knot is characterised by a common motif of eight 
spatially conserved cysteines, which are involved in intra and inter molecular disulfide bonds. (6, 7) 
The two monomers are oriented side-by-side and head-to-tail and held together by one interchain 
disulfide bond. The dimeric structure is also stabilised by a hydrophobic core region. (1, 8) Its 
discovery is credited to Italian scientist Dr. Maria Graziella Persico who first described PlGF in 1991. 
She identified it while investigating the angiogenic potential of human term placental tissue which is 
why this protein was termed “the placental growth factor”. (9) In 1993 the location of the human 
PlGF gene on chromosome 14q24 was isolated and reported to consist of seven exons spanning 13.7 
kb. (10) 
PlGF can exist in multiple isoforms due to alternate splicing encoded by the human PlGF gene. Four 
isoforms of human PlGF are described, PlGF-1, PlGF-2, PlGF-3, and PlGF-4 composed of 131, 152, 203 
and 224 amino acids respectively. PlGF-1 and PlGF-2 are believed to be the major isoforms. (10-14)  
Apart from in size, the PlGF isoforms differ in terms of both their secretion properties and their 
binding affinities. PlGF-1 and PlGF-3 are non-heparin binding diffusible isoforms while PlGF-2 and 
  
PlGF-4 have additional (highly basic 21 amino acids) heparin binding domains. (10, 12, 15) Both 
VEGF-A and PlGF can exist as homodimers and heterodimers (PlGF:PlGF, PlGF:VEGF-A, VEGF-A:VEGF-
A), with PlGF:VEGF heterodimers displaying 20-50-fold less mitogenic activity than VEGF 
homodimers (Figure 1). (16, 17) 
Initial studies conducted in healthy mice in the 1990’s reported a lack of PlGF did not appear to 
confer any negative impact on vascular development. However, when mice deficient in PlGF 
(knockout) were subjected to pathological conditions such as ischaemia, inflammation or cancer, 
they demonstrated severely impaired angiogenic ability. Their inability to adapt and compensate to 
these pathological conditions highlighted the role of PlGF in pathological angiogenesis. (18) 
Receptors 
All members of the VEGF family bind and activate one of the following three homologous tyrosine 
kinase receptors: VEGFR1 (also called fms-like-tyrosine-kinase receptor/Flt-1) VEGFR2 (also called 
Flk-1/KDR) or VEGFR3.  Each of these receptors has a similar structure; a tyrosine kinase extracellular 
seven Ig-like domain connected to an intracellular tyrosine kinase domain via a single 
transmembrane helix. (19-21) Binding induces the mitogenic action of the cell with KDR being 10 
fold stronger than Flt-1 in this regard. (22, 23) VEGF-A can bind to either Flt-1 or KDR (24). Despite 
the structural similarity with VEGF-A, PlGF has been shown to only bind to Flt-1, but it does so with a 
higher affinity than VEGF-A. (25)  In 1996, a non-membrane bound soluble receptor known as 
soluble VEGFR-1 (sFlt-1) was identified. This endogenous protein, synthesised by placental cells 
amongst others, arises from alternative splicing of Flt-1. It retains structural similarity to Flt-1 except 
that it lacks its transmembrane helix and tyrosine kinase intracellular domain, meaning that it can 
circulate freely. (26) Levels of sFlt-1 rise under hypoxic conditions. (27) Circulating sFlt-1 binds PlGF 
and VEGF-A resulting in reduced levels of these proteins available to the anchored cell membrane 
receptors Flt-1 and Flk-1 (Figure 1).   
Function 
PlGF exerts its angiogenic effects by both direct and indirect mechanisms, inducing receptor 
dimerisation and phosphorylation. PlGF directly activates endothelial cells, macrophages and 
haematopoietic progenitor cells by binding to the membrane receptor anchored Flt-1, and in doing 
so may increase the sensitivity of the cell to VEGF-A.  PlGF acts indirectly by displacing VEGF-A from 
Flt-1, allowing VEGF-A to bind instead to the more potent FDK. Lastly, by forming a heterodimer with 
VEGF in mutually expressed cells, PlGF antagonises the angiogenic action of VEGF. (13, 17, 18, 28-30) 
sFlt-1 has anti-angiogenic potential, binding and neutralising PlGF and VEGF in the circulation, 
  
reducing their bio-availability and thus interaction with the cell membrane bound Flt-1 and Flk-1. 
(31, 32) In vitro effects of sFlt-1 include vasoconstriction and endothelial dysfunction. (33) 
 
 
Pre-eclampsia 
As far back as the late 1980’s it had been hypothesised that a circulating factor existed in pre-
eclampsia, which was responsible for the widespread endothelial dysfunction observed. (34) 
Vasculogenesis and angiogenesis are two essential components in development of the utero-
placental circulatory interface in early pregnancy. It has been proposed that early placentation in 
utero occurs in a relatively hypoxic environment with a partial pressure of oxygen as low as 18 mm. 
At approximately 10 weeks gestation, an increase in the partial pressure of oxygen up to 60 mm 
occurs, triggering the proliferation of the cytotrophoblast. This process facilitates invasion of uterine 
spiral arteries of the decidua and myometrium by the cytotrophoblast, allowing these vessels to 
become functionally capable of supplying the high volumes of well-oxygenated blood necessary for 
nourishing a growing fetus. (35, 36)   Should this rise in oxygen pressure fail to occur, the hypoxic 
environment persists, compromising the invasion of the cytotrophoblast. This leads to impaired 
placentation and results in inadequate placental perfusion, hypoxia and potential clinical fetal and 
maternal manifestations: impaired fetal growth and preeclampsia later in pregnancy. (37, 38) 
Studies investigating this circulating factor hypothesis reported significant damage occurring in 
cultured human umbilical vein endothelial cells (HUVECs) exposed to serum from pregnant women 
with pre-eclampsia compared with controls. (37-39)  
Following the discovery of PlGF and its receptors, reports of increased levels of sFlt-1 and reduced 
levels of PlGF and VEGF in pre-eclamptic cases compared to controls were published. (40-43)  Higher 
levels of sFlt-1 have also been reported in; first versus second pregnancies, multiples versus 
singletons, molar and trisomy 13 affected pregnancies, all of these being well established 
independent risk factors for development of pre-eclampsia. (44) Patients receiving VEGF antagonists 
for cancer treatment may develop hypertension and proteinuria, confirming the role of VEGF/PlGF 
blockade in endothelial cell dysfunction. (45, 46) In the early 2000’s, a number of publications 
reported circulating levels of sFlt-1 and PlGF to be altered several weeks before the clinical onset of 
disease in pre-eclampsia. They also showed correlation of these angiogenic factors with the severity 
of disease. (47, 48) Hypoxia alone is enough to trigger sFlt-1 over expression by the placenta, in a 
self-defence type response, to VEGF-A produced by maternal decidual cells. (49) A three stage 
disorder has now been proposed for pre-eclampsia. Initially in early pregnancy from approximately 
  
week 8-18 abnormal remodelling of the spiral arterioles and trophoblast invasion occurs due to a 
deficiency in the pro-angiogenic PlGF and VEGF (Stage 1). The net result of this is impaired placental 
perfusion, which in turn leads to hypoxia and oxidative damage from 20 weeks gestation (Stage 2).  
The pathological placenta then induces apoptosis, inflammation, and releases anti-angiogenic 
factors (sFlt1) and other inflammatory agents such as cytokines in a bid to induce vasoconstriction 
and increase oxygen supply to the hypoxic placenta. The net result of the release of these factors is 
systemic endothelial cell dysfunction and end-organ ischemia, which leads to the classical clinical 
signs and symptoms of pre-eclampsia (Stage 3) which may occur from as early as 20 weeks 
gestation. (50, 51) 
Application 
In the last 15 years, the concept of using sFlt-1 or PlGF, either singly or in combination, as a potential 
screening tool or diagnostic marker for pre-eclampsia has been explored. Screening for pre-
eclampsia appears to make sense. The ability to stratify women in early (11-13 weeks gestation) 
pregnancy as high risk and appropriately tailor antenatal care has huge clinical and economic 
benefits. Currently a huge amount of our antenatal resources are targeted towards routine clinic 
visits including measurement of blood pressure and urinalysis in women at low or moderate risk for 
pre-eclampsia. An effective early screening test would enable those at low risk to be identified, and 
stratified to community based care, with less frequent hospital review. Simultaneously, the early 
identification of women at risk of pre-eclampsia would enable their antenatal care to be 
appropriately tailored and hospital resources to be focused to them. In order to be effective, a 
screening test must demonstrate both clinical and health economic benefits. Clinically relevant 
outcomes would include both maternal and neonatal morbidity. A health economic model analysis 
should assess the cost-effectiveness of a screening strategy relative to no screening at all. (52) 
The recently published ASPRE trial showed a reduction of more than 60% in rates of preterm pre-
eclampsia when aspirin is commenced prior to 14 weeks in women at high risk of same. (53) 
Identification of who exactly is high risk is paramount. The ASPRE trial screened over 25,000 women 
between 11-13 weeks gestation and dichotomised them to high (> 1 in 100) or low risk (<1 in 100) of 
preterm pre-eclampsia.  The predictive model used incorporated maternal serum PlGF, pregnancy 
associated plasma protein–A (PAPP-A), mean arterial pressure (MAP) and uterine artery pulsatility 
index (UtA-PI) as well as maternal factors.  The authors reported a detection rate of 76.7% for 
preterm pre-eclampsia with a false positive rate (FPR) of 10%. This compares to a detection rate of 
just 39% using the traditional approach based on maternal characteristics and medical history alone 
recommended by leading international bodies The National Institute for Health and Clinical 
  
Excellence (NICE) and the Americana College of Obstetricians and Gynaecologists (ACOG). This study 
highlights the potential utility of PlGF as part of combined early pregnancy screening. However prior 
to the introduction of any screening test, both external validation and a health economic analyses 
are necessary, to confirm utility and reproducibility. 
The main use of PlGF in pregnancy currently is in short term prediction of time to delivery in women 
with suspected pre-eclampsia. Having an effective diagnostic test for pre-eclampsia would eliminate 
protracted hospitalisations of women and allow resources to be better utilised.  A systematic review 
in 2015 evaluated trials on placental growth factor (alone or in combination with sFlit-1) as an aid to 
the assessment of women with suspected pre-eclampsia. (54) Four prospective (cohort) studies 
were identified and examined. Meta-analysis was not possible because the studies employed 
different outcome measures, test cut-off points and gestational periods. The PELICAN study showed 
that the PlGF test alone had a very high accuracy for predicting pre-eclampsia requiring delivery 
within 14 days for women presenting with suspected pre-eclampsia between 20 - 35  weeks  of  
gestation.  For  a  test  cut-off  <100 pg/mL, PlGF alone showed 96% sensitivity (95% CI, 89–99), 56% 
specificity (95% CI, 49–63), 44% positive predictive value (PPV) (95% CI, 36–52), and 98% negative 
predictive value (NPV) (95% CI, 93–100)  (55).  The PROGNOSIS  study  evaluated whether the sFlt-
1:PlGF ratio is predictive of  the  short-term  absence  or  presence  of  pre-eclampsia  in  women  
with suspicion of pre-eclampsia  between 24 and 36+6  weeks of pregnancy. It reported a sFlt-1:PlGF 
ratio ≤ 38 had a NPV in the subsequent week of 99.3% (95% confidence interval [CI] 97.9–99.9). In 
2016 NICE published guidance on the use of PlGF testing based on this review. The Triage PlGF test 
and the Elecsys immunoassay sFlt-1:PlGF ratio, used with standard clinical assessment and 
subsequent clinical follow-up, were recommended to help rule-out pre-eclampsia in women 
presenting with suspected pre-eclampsia between 20 weeks and 34 weeks plus 6 days of gestation.  
NICE recommended that these tests should not yet be used to diagnose pre-eclampsia until further 
research is available, specifically on how an abnormal PlGF result would affect management 
decisions regarding timing and gestation of delivery and the outcomes associated with this. (56) 
Interventional studies were recommended to confirm the clinical utility of the results to date. Some 
smaller cohort studies (MAPPLE) with unblinded PlGF testing have reported a lowering of gestational 
age at delivery and an increase in neonatal prematurity related morbidity.  This highlights the 
importance of conducting appropriately powered trials before PlGF testing is routinely adapted into 
clinical practice. (57) A number of randomised controlled trials are currently ongoing, the UK 
PARROT trial and the PARROT Ireland trial among these, with results expected in 2019. (58)  
  
The prospect of using PlGF as a therapeutic agent has also begun to be considered.  Recent studies in 
mice have demonstrated that administration of VEGF early in pregnancy prevents the development 
of pre-eclampsia (59) and reduction in circulating sFlt-1 alleviated pre-eclampsia like symptoms 
again in a mouse model. (60) A pilot study on the safety and efficacy of therapeutic apheresis for 
preterm pre-eclampsia was conducted on 11 pregnant women with pre-eclampsia ranging from 23 
to 32 weeks gestation. A reduction in levels of circulating sFlt-1 was achieved with combinations of 
single or multiple plasma apheresis. Overall a prolongation of pregnancy without major adverse 
maternal or fetal consequences was seen. (61) A case controlled prospective study is currently 
ongoing, collecting maternal plasma and serum from patients with both pre-eclampsia and normal 
pregnancy for in vitro validation of new therapeutics based on extra-corporal removal of sFlt-1 
(APHERESE) (62)” Also currently recruiting is an interventional trial of a medical apheresis device for 
Flt-1 in pre-eclamptic women (SAVE). (63) 
These studies suggest the potential utility of early pro-angiogenic therapies in treating pre-eclampsia 
in the future.  
Assays 
A variety of different assays are now commercially available for quantification of PlGF alone or in 
combination with sFlt-1; Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 
1-2-3 test,  The Quantikine Human PlGF Immunoassay (R&D systems) and BRAHMS sFlt-1 
Kryptor/BRAHMS PlGF plus Kryptor PE ratio. Most of these are laboratory based and require 
significant infrastructure available to use while the Triage PlGF test is  point of care and could be 
easily integrated to antenatal clinical care algorithms in developing countries. Importantly to note, 
the normal reference values of PlGF obtained with one platform may not be interchangeable with 
others. Validation studies, head-to-head comparative studies, and cost effective analyses comparing 
these platforms are required as the performance and costs of these may differ between assays.  
Outside Pregnancy  
PlGF is more than just a pregnancy specific biomarker. Although originally identified in the placenta, 
PlGF is also expressed in heart, lung, thyroid, adipose tissue and skeletal muscle. Its absence impairs 
angiogenesis and arteriogenesis during tumour growth and heart, limb and ocular ischaemia. (18, 
64-69) Patients with sickle cell disease are noted to have increased levels of PlGF, expressed by bone 
marrow erythroid cells under hypoxic conditions, with levels of PlGF correlating with degree of 
disease activity. An association between PlGF and β-thalassaemia has also been reported, with levels 
of PlGF positively correlating with other markers of haemolysis such as lactate dehydrogenase, uric 
  
acid and reticulocyte counts in this group.  (70-72) Whether PlGF may act as a biomarker of disease 
activity or have a role in potential targeted therapies in patients with haemaglobinopathies remains 
the subject of ongoing research. (73)  More recently, PlGF has been identified as a possible 
contributor in haematologic malignancies, with both PlGF and sFlt-1 expression increased in samples 
from patients with chronic myeloid leukaemia (CML), acute myeloid leukaemia (AML) and acute 
lymphoid leukaemia (ALL). This is in contrast to the increased PlGF and reduced sFlt-1 expression 
seen in patients with pre-eclampsia. The exact mechanism of action of the angiogenic PlGF and anti-
angiogenic sFlt-1 in these malignancies is as yet not fully understood, but the potential of targeted 
anti-PlGF therapy is being explored. (74-76) A recent study on thyroid carcinoma found significantly 
higher levels of PlGF in metastatic disease, suggesting that antagonising PlGF in this setting may be a 
promising therapy to suppress cancer metastasis (77). In the pathological models studied, the 
absence of PlGF impairs the associated inflammation and angiogenesis and confers a general 
reduction in pathological changes. (78)   
Conclusion 
PlGF plays an integral role in the development of a normal pregnancy and aberrations in PlGF 
concentrations are associated with adverse pregnancy outcomes, in particular pre-eclampsia. The 
universal integration of PlGF into antenatal assessment of women with suspected preterm pre-
eclampsia is dependent on results of current RCTs.  The role of PlGF as a as a biomarker of disease 
outside of pregnancy shows promise while its potential as a possible therapeutic for pre-eclampsia 
and some malignancies warrants further research. 
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Figure 1: PlGF and VEGF hetero and homodimer protein structures and their respective membrane 
bound receptors Flt-1 ad Flk-1 and the freely circulating receptor sFlt-1 
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Highlights: 
 PlGF plays an integral role in the development of a normal pregnancy  
 Aberrations in PlGF are associated with adverse pregnancy outcomes, in particular 
pre-eclampsia 
 The integration of PlGF into clinical care is dependent on results of current RCTs 
 The role of PlGF as a as a biomarker of disease or therapeutic agent outside of 
pregnancy shows promise 
 
 
